EMA/758312/2016

European Medicines Agency decision

P/0342/2016

of 2 December 2016

on the agreement of a paediatric investigation plan for recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689) (EMEA-001886-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0342/2016

of 2 December 2016

on the agreement of a paediatric investigation plan for recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689) (EMEA-001886-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by CSL Behring GmbH on 15 October 2015 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 October 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689), powder and solvent for solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

This decision is addressed to CSL Behring GmbH, Emil-von-Behring Str. 76, 35041 – Marburg, Germany.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

EMA/PDCO/535195/2016
London, 14 October 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan

EMEA-001886-PIP01-15

Scope of the application

Active substance(s):

Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689)

Condition(s):

Treatment of Haemophilia A

Treatment of Haemophilia B

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

CSL Behring GmbH

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, CSL Behring GmbH submitted for agreement to the European Medicines Agency on 15 October 2015 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 30 November 2015.

Supplementary information was provided by the applicant on 18 July 2016. The applicant proposed modifications to the paediatric investigation plan.

A meeting with the Paediatric Committee took place on 12 October 2016.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition

Treatment of Haemophilia A

2.1.1. Indication(s) targeted by the PIP

Treatment of Haemophilia A with inhibitors

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	2	**Study 1** Multicentre, open-label, multiple-dose, dose escalation study to evaluate pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in children and adults with haemophilia (A or B) and inhibitors. **Study 2** Multicentre open-label multi-dose study to investigate PK, efficacy and safety of prophylactic treatment of CSL689 in children and adults with congenital haemophilia with inhibitors.

Area	Number of measures	Description
Extrapolation, modelling and simulation studies	5	**Study 3** Population PK model to describe the PK of CSL689 in healthy subjects of 18 years of age or older (using data from Study CSL689_1001). **Study 4** Population PK model 1: To describe the PK of CSL689 in subjects with congenital haemophilia with inhibitors from 12 years of age. Population PK model 2: To describe the PK of CSL689 in subjects with congenital haemophilia with inhibitors in all age groups, including children less than 12 years of age (using data from Study CSL689_1001 and 2001). **Study 5** Population PK model 3 (Final model): To describe the PK of CSL689 in subjects with congenital haemophilia with inhibitors in all age groups (using data from study CSL689_1001, 2001 and 3001). **Study 6** Extrapolation of exposure in paediatric subjects less than 12 years of age based on an adult/ adolescent PopPK model, published data on Eptacog alfa (activated)(rFVIIa), data reported for fusion protein products from internal CSLB experience (rIX-FP/ CSL654) and allometric scaling. **Study 7** Extrapolation of exposure in paediatric subjects less than 12 years of age based on an final PopPK model, published data on Eptacog alfa (activated)(rFVIIa), data reported for fusion protein products from internal CSLB experience (rIX-FP/ CSL654) and allometric scaling.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

2.2. Condition

Treatment of Haemophilia B

2.2.1. Indication(s) targeted by the PIP

Treatment of Haemophilia B with inhibitors

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Powder and solvent for solution for injection

2.2.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	2	**Study 1** Same as for condition “Treatment of Haemophilia A” **Study 2** Same as for condition “Treatment of Haemophilia A”
Extrapolation, modelling and simulation studies	5	**Study 3** Same as for condition “Treatment of Haemophilia A” **Study 4** Same as for condition “Treatment of Haemophilia A” **Study 5** Same as for condition “Treatment of Haemophilia A” **Study 6** Same as for condition “Treatment of Haemophilia A” **Study 7** Same as for condition “Treatment of Haemophilia A”
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2020
Deferral for one or more measures contained in the paediatric investigation plan:	No